Scilex Holding (SCLXW) Operating Expenses (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Operating Expenses of $40.8 million in Q1 2026, down 64.81% quarter-over-quarter from $115.9 million in Q4 2025, and up 23.95% on a YoY basis from $32.9 million in Q1 2025.
Scilex Holding (SCLXW) Operating Expenses (2020 - 2026) Analysis & Trends
Scilex Holding's Operating Expenses history runs 7 years deep, the most recent figure standing at $40.8 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 23.95% year-over-year to $40.8 million; the TTM figure through Mar 2026 stood at $384.1 million (up 169.52% YoY), while the FY2025 annual figure was $376.3 million, up 168.78% from the prior year.
- Operating Expenses was $40.8 million for Q1 2026 at Scilex Holding, down from $115.9 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $197.1 million in Q3 2025 to a low of $15.6 million in Q1 2022.
- Historically, Operating Expenses has averaged $46.9 million across 5 years, with a median of $32.9 million in 2025.
- Biggest YoY gain for Operating Expenses was 11168.15% in 2022; the steepest drop was 52.42% in 2022.
- A 5-year view of Operating Expenses shows it stood at $31.7 million in 2022, then gained by 0.45% to $31.8 million in 2023, then surged by 36.09% to $43.3 million in 2024, then jumped by 167.76% to $115.9 million in 2025, then slumped by 64.81% to $40.8 million in 2026.
- The last three Operating Expenses figures came in at $40.8 million (Q1 2026), $115.9 million (Q4 2025), and $197.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -5.14 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 6.72 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 9.59 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 11.01 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 19.82 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 5.95 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 4.37 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 5.50 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 8.25 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 40.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.78 Mn |
| Dec 31, 2025 | 115.88 Mn |
| Sep 30, 2025 | 197.07 Mn |
| Jun 30, 2025 | 30.40 Mn |
| Mar 31, 2025 | 32.90 Mn |
| Dec 31, 2024 | 43.28 Mn |
| Sep 30, 2024 | 34.35 Mn |
| Jun 30, 2024 | 31.99 Mn |
| Mar 31, 2024 | 30.36 Mn |
| Dec 31, 2023 | 31.80 Mn |
| Sep 30, 2023 | 48.92 Mn |
| Jun 30, 2023 | 35.40 Mn |
| Mar 31, 2023 | 36.06 Mn |
| Dec 31, 2022 | 31.66 Mn |
| Sep 30, 2022 | 21.99 Mn |
| Jun 30, 2022 | 19.40 Mn |
| Mar 31, 2022 | 15.62 Mn |
| Dec 31, 2021 | 66.53 Mn |
| Sep 30, 2021 | 283,346.00 |
| Jun 30, 2021 | 172,140.00 |